- Home
- THR vs MLYS Comparison
THR vs MLYS Comparison
Compare THR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THR
- MLYS
- Stock Information
- Founded
- THR 1954
- MLYS 2019
- Country
- THR United States
- MLYS United States
- Employees
- THR N/A
- MLYS N/A
- Industry
- THR Industrial Machinery/Components
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- THR Energy
- MLYS Health Care
- Exchange
- THR Nasdaq
- MLYS Nasdaq
- Market Cap
- THR 1.0B
- MLYS 893.0M
- IPO Year
- THR 2011
- MLYS 2023
- Fundamental
- Price
- THR $28.43
- MLYS $14.66
- Analyst Decision
- THR Strong Buy
- MLYS Strong Buy
- Analyst Count
- THR 1
- MLYS 3
- Target Price
- THR $38.00
- MLYS $27.00
- AVG Volume (30 Days)
- THR 226.7K
- MLYS 2.0M
- Earning Date
- THR 02-06-2025
- MLYS 05-08-2025
- Dividend Yield
- THR N/A
- MLYS N/A
- EPS Growth
- THR N/A
- MLYS N/A
- EPS
- THR 1.37
- MLYS N/A
- Revenue
- THR $491,781,000.00
- MLYS N/A
- Revenue This Year
- THR $0.92
- MLYS N/A
- Revenue Next Year
- THR $8.63
- MLYS N/A
- P/E Ratio
- THR $21.15
- MLYS N/A
- Revenue Growth
- THR 0.47
- MLYS N/A
- 52 Week Low
- THR $25.76
- MLYS $8.24
- 52 Week High
- THR $35.93
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- THR 43.61
- MLYS 56.01
- Support Level
- THR $29.02
- MLYS $16.15
- Resistance Level
- THR $30.70
- MLYS $17.21
- Average True Range (ATR)
- THR 0.89
- MLYS 1.30
- MACD
- THR -0.07
- MLYS -0.03
- Stochastic Oscillator
- THR 18.05
- MLYS 36.19
About THR Thermon Group Holdings Inc.
Thermon Group Holdings Inc is a United States-based company that provides engineered thermal solutions for process industries. The company's product portfolio comprises electric heat tracing cables, steam tracing components, tubing bundles, and instrument and control products, as well as complementary product lines. It also provides turnkey services and design and engineering services. The company's customers include large engineering, procurement, and construction companies; oil and gas companies; commercial subcontractors; electrical component distributors; and others. The company has a presence, with the United States, Canada, and Europe being its top three markets and contributing the majority of its sales.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.